LAUSR

Prostate cancer (PCa), the most common, non-cutaneous male malignancy (1), is primarily driven by androgen signaling. Thus, clinical management of the disseminated disease is dominated by ever-improving androgen receptor (AR) pathway inhibitors (ARPIs) that have contributed to 30–40% decline in disease-specific mortality observed over the last two decades (2). Nonetheless nearly all ARPI therapy patients eventually develop resistance to these agents (2,3), calling for the development of novel targeted therapeutics for additional molecular lesions in PCa.